The company presented a growth strategy at a major healthcare conference, emphasizing strong ongoing performance of its hereditary angioedema drug franchise. It highlighted a pending acquisition of Astria Therapeutics and reported progress on an early-stage program for Netherton syndrome. Management also provided a financial outlook extending to 2026, signaling confidence in its future pipeline and commercial execution.